Treatment of Focal Segmental Glomerulosclerosis in Low- and Middle-Income Countries: Emerging Extracorporeal Therapies
Blood Purification · 20.06.2026 · 1-17
DOI: 10.1159/000553218 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood Purification, online erschienen am 20.06.2026. Verfasst von Flora R Gallegos und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio, USA. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Focal segmental glomerulosclerosis (FSGS) involves glomerular scarring and podocyte injury. FSGS treatment typically involves the use of corticosteroids and immunosuppressants. In patients with steroid-resistant FSGS, however, no ideal treatment exists. Extracorporeal therapies such as plasma exchange and low-density lipoprotein apheresis may be promising options for managing lipid-mediated nephrotoxicity found in patients with steroid-resistant FSGS. Unfortunately, these extracorporeal techniques are inaccessible in many low- and middle-income countries (LMICs) due to high costs and infrastructure challenges.
Methods
The use of extracorporeal therapies for FSGS management was evaluated at a single center. Additionally, a literature search was conducted across multiple databases to identify studies that explored FSGS treatment modalities in LMICs. Eligibility was assessed based on discussion of viability, efficacy, and application of therapies.
Results
It was found that double-filtration plasmapheresis (DFPP) and other extracorporeal therapy modalities have exhibited potential in attaining remission in patients with steroid-resistant FSGS, primarily in settings with limited resources.
Discussion
The development of improvements in extracorporeal therapy, such as modified DFPP, may offer cost improvements due to reduced fluid replacement, which may lead to increased use in LMICs. Twinning programs and governmental intervention may be used to address the gaps in FSGS care in LMICs. Future efforts involve expanding access to plasmapheresis in the management of FSGS, especially in resource-limited settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio, USA.
- Institute of Kidney Diseases and Research Center and Dr. H L Trivedi Institute of Transplantation Sciences, Gujarat University of Transplantation Sciences, Ahmedabad, India.
- Department of Nephrology, Akron Children's Hospital, Akron, Ohio, USA.
- Pediatric Nephrology and Pediatric Kidney Transplantation, Kidney and Urology Institute, Medanta, The Medicity Hospital, Gurgaon, India.
- Department of Nephrology, Akron Nephrology Associates, Cleveland Clinic Akron General, Akron, Ohio, USA.
- Department of Pediatric Nephrology, Hacettepe University Medical Faculty, Ankara, Turkey.
Zitieren
APA
Gallegos, F. R., Vala, K., Hu, J., Sethi, S. K., Spyres, D., Safadi, R., Tanna, S., Kapadia, S., Duzova, A., Antwi, S. K., & Raina, R. (2026). Treatment of Focal Segmental Glomerulosclerosis in Low- and Middle-Income Countries: Emerging Extracorporeal Therapies. Blood Purification, 1-17. https://doi.org/10.1159/000553218
Vancouver
Gallegos FR, Vala K, Hu J, Sethi SK, Spyres D, Safadi R, et al. Treatment of Focal Segmental Glomerulosclerosis in Low- and Middle-Income Countries: Emerging Extracorporeal Therapies. Blood Purification. 2026:1-17. doi:10.1159/000553218
BibTeX
@article{Gallegos2026,
author = {Gallegos, Flora R and Vala, Kinnari and Hu, Jieji and Sethi, Sidharth Kumar and Spyres, Dean and Safadi, Rama and Tanna, Shay and Kapadia, Shahenaz and Duzova, Ali and Antwi, Sampson K and Raina, Rupesh},
title = {Treatment of Focal Segmental Glomerulosclerosis in Low- and Middle-Income Countries: Emerging Extracorporeal Therapies},
journal = {Blood Purification},
year = {2026},
pages = {1--17},
doi = {10.1159/000553218}
}
EUVIMED